参考文献/References:
[1]Siegel R, Ma J, Zou Z, et al. Cancer statistics,2014.CA Cancer J Clin,2014,64(1):9-29.
[2]Della Pepa C, Tonini G, Pisano C, et al. Ovarian cancer standard of care: are there real alternatives? Chin J Cancer,2015,34(1):17-27.
[3]Kemp Z, Ledermann J. Update on first-line treatment of advanced ovarian carcinoma. Int J Womens Health,2013,5(1):45-51.
[4]Bagley CM Jr，Young RC，Schein PS，et al．Ovarian carcinoma metastatic to the diaphragm-frequently undiagnosed at laparotomy: a preliminary report. Am J Obstet Gynecol,1973,116(3):397-400.
[5]熊维,曹莉莉,蒋路频,等.早期卵巢上皮性癌经腹腔镜与开腹行全面分期手术的临床对比分析.中华妇产科杂志,2017,52(2):103-109.
[6]Fagotti A, Ferrandina G, Fanfani F，et al．A laparoscopy-based score to predict surgical outcome in patients with advanced ovarian carcinoma: a pilot study. Ann Surg Oncol,2006,13(8):1156-1161.
[7]李萌，熊光武.晚期卵巢癌、输卵管癌及原发性腹膜癌腹腔镜肿瘤细胞减灭术的安全性及有效性研究.中国微创外科杂志,2012,12(2):98-100.
[8]陈婵娟,林云笑,陈昌南,等.替吉奥治疗卵巢癌术后化疗后生化复发患者的临床研究.中国现代药物应用,2017,11(5):87-88.
[9]刘永珠,胡庆兰,陈日利,等.腹腔镜与开腹手术治疗早期卵巢癌的比较.中国微创外科杂志,2014,14（7）:597-599.
[10]Rutten MJ, van Meurs HS, van de Vrie R，et al. Laparoscopy to predict the result of primary cytoreductive surgery in patients with advanced ovarian cancer: a randomized controlled trial. J Clin Oncol,2017,35(6):613-621.
[11]Corrado G, Mancini E, Cutillo G, et al．Laparoscopic debulking surgery in the management of advanced ovarian cancer after neoadjuvant chemotherapy. Int J Gynecol Cancer, 2015,25(7):1253-1257.
[12]Magrina JF，Cetta RL，Chang YH，et al. Analysis of secondary cytoreduction for recurrent ovarian cancer by robotics, laparoscopy and laparotomy. Gynecol Oncol,2013,129(2):336-340.
[13]Nezhat FR，Finger TN，Vetere P，et al. Comparison of perioperative outcomes and complication rates between conventional versus robotic-assisted laparoscopy in the evaluation and management of early, advanced, and recurrent stage ovarian, fallopian tube, and primary peritoneal cancer. Int J Gynecol Cancer,2014,24(3):600-607.
[14]Heitz F，Ognjenovic D，Harter P，et al．Abdominal wall metastases in patients with ovarian cancer after laparoscopic surgery: incidence，risk factors，and complications. Int J Gynecol Cancer,2010,20(1):41-46.
[15]Nezhat FR，DeNoble SM，Liu CS，et al．The safety and efficacy of laparoscopic surgical staging and debulking of apparent advanced stage ovarian，fallopian tube，and primary peritoneal cancers．JSLS,2010,14(2):155-168.
[16]Zheng H, Gao YN. Primary debulking surgery or neoadjuvant chemotherapy followed by interval debulking surgery for patients with advanced ovarian cancer. Chin J Cancer Res,2012,24(4):304-309.
[17]Chereau E, Lavoue V, Ballester M, et al. External validation of a laparoscopic-based score to evaluate resectability for patients with advanced ovarian cancer undergoing interval debulking surgery. Anticancer Res,2011,31(12):4469-4474.
[18]Gómez-Hidalgo NR, Martinez-Cannon BA, Nick AM, et al．Predictors of optimal cytoreduction in patients with newly diagnosed advanced-stage epithelial ovarian cancer: time to incorporate laparoscopic assessment into the standard of care. Gynecol Oncol,2015,137(3):553-558.